Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?

As of Oct. 23, 2026, VanEck Biotech ETF (BBH) returned 39.7% over the trailing year and charges a 0.35% expense ratio, compared with 37.0% and 0.59% for Invesco Biotechnology & Genome ETF (PBE). Over five years, $1,000 grew to $1,287 in BBH versus $1,346 in PBE; PBE also has a higher trailing yield at 1.3% versus BBH’s 0.4%. The article presents BBH as the lower-cost, concentrated large-cap option and PBE as the higher-yield, factor-driven alternative.

Analysis

This is a portfolio-construction choice, not evidence of a broad biotech earnings inflection. BBH’s market-cap weighting makes the relative bet increasingly about a handful of mature franchises: positive news at its largest holdings can lift the fund, but product concentration, patent exposure, or pipeline disappointments can also dominate returns. PBE’s quarterly factor reset can capture broadening momentum, yet may rotate into recent winners late and suffer if leadership reverses; its recent five-year edge does not establish that the factor mix will persist. The quoted yield should not be treated as dependable income until distributions are split between portfolio dividends and realized gains.

Over days to weeks, no durable catalyst follows from the comparison itself. Over 1–3 months, watch biotech breadth, factor leadership, and clinical/regulatory read-throughs; over 6–18 months, product-cycle outcomes, pricing pressure, and large-pharma deal activity matter more than the 24bp fee gap. The main contrarian point: the apparent yield advantage may be economically less meaningful than it looks, while lower fees do not compensate automatically for BBH’s top-holding concentration. Verify current holdings, distribution composition, tracking, and trading spreads before expressing a relative-value view.

Key Decisions for Investors

• No immediate ETF switch on the reported performance comparison alone. Treat the funds as different exposures, and compare current holdings and total-return performance over a common period before allocating.
• Conditional relative-value watch: favor BBH over PBE if leadership remains concentrated in established large-cap biotech; favor PBE if gains broaden and its screened holdings sustain earnings and price momentum. Keep the position small until holdings-level attribution confirms the intended exposure.
• For BBH, monitor AMGN, GILD, and VRTX for material guidance, product, or pipeline changes; for PBE, monitor NTRA, ILMN, and BIIB alongside quarterly rebalancing. A deterioration in these names or sharp breadth reversal would weaken the respective fund thesis.
• Falsifiers: persistent PBE outperformance after fees across a full momentum reversal would challenge the large-cap concentration preference; broad biotech weakness or adverse clinical, regulatory, or pricing developments would undermine both funds. Check whether PBE distributions are dividends or realized gains before using its yield as an income rationale.